Evidence of BCR-ABL1-positive progenitor spread in blood during molecular recurrence after TKI discontinuation in chronic myeloid leukemia (CML)

Ali G Turhan; Patricia Hugues; Nathalie Sorel; Christophe Desterke; Jean-Henri Bourhis; Annelise Bennaceur-Griscelli; Jean-Claude Chomel

doi:10.1080/10428194.2020.1734593

Evidence of BCR-ABL1-positive progenitor spread in blood during molecular recurrence after TKI discontinuation in chronic myeloid leukemia (CML)

Leuk Lymphoma. 2020 Jul;61(7):1719-1723. doi: 10.1080/10428194.2020.1734593. Epub 2020 Mar 3.

Authors

Ali G Turhan^{1

2

3

4

5}, Patricia Hugues¹, Nathalie Sorel⁶, Christophe Desterke^{1

2}, Jean-Henri Bourhis⁷, Annelise Bennaceur-Griscelli^{1

2

3

4

5}, Jean-Claude Chomel^{1

6}

Affiliations

¹ INSERM UMR-S935, Campus CNRS, Villejuif, France.
² Paris Saclay, Faculté de Médecine, Université Paris Sud, Le Kremlin-Bicêtre, France.
³ INGESTEM-ESTeam Paris Sud, Villejuif, France.
⁴ Service d'Onco-Hématologie, AP-HP Hôpitaux Universitaires Paris Sud, Hôpital Paul Brousse, Villejuif, France.
⁵ Service d'Hématologie, AP-HP Hôpitaux Universitaires Paris Sud, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
⁶ CHU de Poitiers, Service de Cancérologie Biologique, Poitiers, France.
⁷ Département d'Hématologie, Institut Gustave Roussy, Villejuif, France.

PMID: 32122205
DOI: 10.1080/10428194.2020.1734593

No abstract available

Publication types

Letter

MeSH terms

Fusion Proteins, bcr-abl / genetics
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
Protein Kinase Inhibitors / therapeutic use

Substances

Protein Kinase Inhibitors
Fusion Proteins, bcr-abl